OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Oncology Fellows

home / publications / oncology-fellows
  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • All
  • Business Management
Oncology Fellows, Vol. 14 No. 2

Vol. 15/No. 2

Volume: 14

View Issue
Download Issue
Vol. 15-No. 1

Vol. 15-No. 1

Volume: 15

Issue: 1

View Issue
Vol. 14/No. 4

Vol. 14/No. 4

Volume: 14

Issue: 4

View Issue
Vol. 14/No. 3

Vol. 14/No. 3

Volume: 14

Issue: 3

View Issue
Oncology Fellows Vol. 14/No. 2

Vol. 14/No. 2

Volume: 14

Issue: 2

View Issue
Vol. 14/No. 1

Vol. 14/No. 1

Volume: 14

Issue: 1

View Issue
Vol. 13/No. 4

Vol. 13/No. 4

Volume: 13

Issue: 4

View Issue
Vol. 13/No. 3

Vol. 13/No. 3

Volume: 13

Issue: 3

View Issue
Vol. 13/No. 2

Vol. 13/No. 2

Volume: 13

Issue: 2

View Issue
Vol. 13/No. 1

Vol. 13/No. 1

Volume: 13

Issue: 1

View Issue
December 2020

December 2020

Volume: 12

Issue: 4

View Issue
Oncology Fellows September 2020

September 2020

Volume: 1

Issue: 1

View Issue
June 2020

June 2020

Volume: 12

Issue: 2

View Issue
March 2020

March 2020

Volume: 12

Issue: 1

View Issue
December 2019

December 2019

Volume: 11

Issue: 3

View Issue
September 2019

September 2019

Volume: 11

Issue: 3

View Issue
March 2019

March 2019

Volume: 11

Issue: 1

View Issue
June 2019

June 2019

Volume: 11

Issue: 2

View Issue
December 2018

December 2018

Volume: 10

Issue: 4

View Issue
September 2018

September 2018

View Issue
June 2018

June 2018

View Issue
March 2018

March 2018

View Issue
December 2017

December 2017

View Issue
September 2017

September 2017

View Issue
June 2017

June 2017

View Issue
March 2017

March 2017

View Issue
December 2016

December 2016

View Issue
September 2016

September 2016

Volume: 8

Issue: 3

View Issue
June 2016

June 2016

View Issue
March 2016

March 2016

Volume: 8

Issue: 1

View Issue
12>

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact